Health ❯ Healthcare ❯ Drug Development

Monoclonal Antibodies

Next-Generation Treatments Belantamab Mafodotin Darzalex Faspro Bispecific T-cell Engagers Bevacizumab IL-23 Inhibitors

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Regulatory discussions are planned following independent confirmation of benefit.

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial